ORINASE Drug Patent Profile

Which patents cover Orinase, and what generic alternatives are available?

Orinase is a drug marketed by Pharmacia And Upjohn and is included in two NDAs.

The generic ingredient in ORINASE is tolbutamide sodium. There are two drug master file entries for this compound. Additional details are available on the tolbutamide sodium profile page.

Summary for ORINASE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	3
Patent Applications:	4,590
DailyMed Link:	ORINASE at DailyMed

Recent Clinical Trials for ORINASE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Corcept Therapeutics	Phase 1
Daiichi Sankyo, Inc.	Phase 1
Novartis	Phase 2

See all ORINASE clinical trials

US Patents and Regulatory Information for ORINASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	ORINASE	tolbutamide	TABLET;ORAL	010670-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmacia And Upjohn	ORINASE	tolbutamide	TABLET;ORAL	010670-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmacia And Upjohn	ORINASE DIAGNOSTIC	tolbutamide sodium	INJECTABLE;INJECTION	012095-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Orinase Market Dynamics and Financial Trajectory: Tolbutamide’s Decline in the Diabetes Drug Market

Last updated: August 14, 2026

Orinase was the original U.S. brand for tolbutamide, a first-generation sulfonylurea approved in the late 1950s for type 2 diabetes. Its commercial trajectory followed the standard lifecycle of an early small-molecule medicine: rapid adoption after launch, loss of differentiation after generic competition, and sustained decline as safer and more effective diabetes therapies displaced first-generation sulfonylureas.

Orinase no longer has a meaningful branded market position. Tolbutamide remains a low-cost generic product in some markets, but its use is limited by hypoglycemia risk, short duration of action, cardiovascular safety concerns, and competition from metformin, second-generation sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and insulin products.

What drug was Orinase and who marketed it?

Orinase was the brand name for tolbutamide, an oral sulfonylurea used to lower blood glucose in adults with type 2 diabetes. The product was associated with The Upjohn Company, which commercialized tolbutamide in the United States after its approval.

Attribute	Orinase
Active ingredient	Tolbutamide
Drug class	First-generation sulfonylurea
Therapeutic area	Type 2 diabetes
Route	Oral
Common historical strength	500 mg tablets
Original U.S. marketer	The Upjohn Company
FDA approval period	Late 1950s
Current branded status	No material branded market
Current market form	Generic tolbutamide, where commercially available
Primary mechanism	Stimulates pancreatic insulin secretion
Principal safety issue	Hypoglycemia
Commercial position	Legacy, low-cost generic therapy

Tolbutamide stimulates insulin release from pancreatic beta cells. Unlike newer diabetes drugs, it does not provide cardiovascular or renal outcome benefits and has limited utility when endogenous insulin production has materially declined.

When did Orinase lose exclusivity?

Orinase lost meaningful commercial exclusivity decades ago. Its original small-molecule patent protection, if any remained after launch, expired long before the modern pharmaceutical patent environment. No current branded patent estate is associated with Orinase as a commercially relevant product.

The economically important exclusivity events were therefore historical rather than current:

Period	Market event	Commercial effect
Late 1950s	FDA approval and launch of tolbutamide	Created the first major oral sulfonylurea market
1960s	Expansion of oral diabetes treatment	Supported broad primary-care adoption
1970s	University Group Diabetes Program safety controversy	Weakened confidence in first-generation sulfonylureas
1980s-1990s	Entry of newer sulfonylureas and metformin	Reduced clinical differentiation
1990s-2000s	Generic substitution and low-cost competition	Eliminated most branded pricing power
2000s onward	Growth of newer drug classes	Reduced utilization of tolbutamide
Current period	Generic legacy use	Small, price-sensitive market

The FDA’s historical labeling for tolbutamide includes warnings associated with hypoglycemia and cardiovascular risk. The University Group Diabetes Program reported excess cardiovascular mortality in patients treated with tolbutamide compared with certain alternatives, leading to a long-running regulatory and clinical debate over the first-generation sulfonylurea class (University Group Diabetes Program, 1970; U.S. Food and Drug Administration, n.d.-a).

What is the FDA regulatory status of Orinase?

Orinase is not a current growth product in the FDA-regulated U.S. diabetes market. The branded product has no meaningful contemporary commercial presence, while generic tolbutamide may remain listed or intermittently marketed depending on manufacturer and supply conditions.

FDA approval of tolbutamide predates the modern New Drug Application framework as it is generally used for current products. Historical records and legacy labeling provide the primary regulatory basis for understanding Orinase.

Tolbutamide is regulated as an oral antidiabetic drug. Its prescribing information identifies several limitations:

• It can cause severe hypoglycemia.
• It requires functioning pancreatic beta cells to produce insulin.
• It is not appropriate for type 1 diabetes.
• It has a shorter duration of action than several later-generation sulfonylureas.
• Elderly patients and patients with renal or hepatic impairment have greater hypoglycemia risk.
• It does not offer the outcome advantages associated with modern cardiometabolic therapies.

Current treatment guidelines generally place metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and other newer therapies ahead of tolbutamide when clinical and economic circumstances permit (American Diabetes Association Professional Practice Committee, 2024).

What patents protected Orinase and tolbutamide?

No active patent estate is commercially relevant to Orinase today. Tolbutamide is an old, conventional small molecule. Any composition-of-matter protection associated with its original development expired many years ago.

The product’s historical protection was based primarily on:

1. Early compound and pharmaceutical composition patents.
2. Regulatory approval and physician adoption.
3. Manufacturing know-how and tablet production capability.
4. Brand recognition under the Orinase name.

None of these factors now provides meaningful market exclusivity. There are no known current formulation patents, method-of-use patents, delivery-system patents, or manufacturing patents that materially constrain generic tolbutamide competition in the United States.

Are there Orange Book patents for Orinase?

Orinase does not have a commercially relevant current Orange Book patent position. The Orange Book is designed to identify approved drug products and listed patents that can affect generic approval. A legacy product such as Orinase does not retain practical patent leverage merely because it was once approved.

A generic applicant challenging a current listed patent would ordinarily use an abbreviated new drug application and may submit a Paragraph IV certification. That framework has no meaningful current role for Orinase because its historical exclusivity has expired and no active branded product strategy appears to support patent enforcement.

How did safety concerns affect Orinase sales?

Safety concerns materially weakened tolbutamide’s long-term commercial position. The University Group Diabetes Program study reported higher cardiovascular mortality in patients receiving tolbutamide than in certain comparator groups. The findings led to regulatory warnings for oral hypoglycemic agents and influenced subsequent prescribing behavior.

The study did not eliminate sulfonylureas from clinical practice, but it changed the risk-benefit assessment for tolbutamide. Later sulfonylureas, including glyburide, glipizide, and glimepiride, gained market share because they offered more convenient dosing, longer or more predictable activity, or stronger commercial support.

Tolbutamide’s safety profile also became less attractive as treatment moved toward therapies with lower hypoglycemia risk and demonstrated cardiovascular, renal, or weight-related benefits.

How did competing diabetes drugs displace Orinase?

Orinase faced two forms of competition: therapeutic substitution and generic price competition.

Therapeutic substitution

Metformin became the foundational oral treatment for type 2 diabetes because of its efficacy, low cost, weight neutrality or modest weight benefit, and lower hypoglycemia risk when used alone. It also avoided the insulin-secretagogue mechanism that defines tolbutamide.

Second-generation sulfonylureas displaced tolbutamide within the same class. These agents generally offered more convenient dosing and stronger physician familiarity in later treatment algorithms.

Newer classes then expanded the competitive gap:

Drug class	Competitive advantage over tolbutamide
Metformin	Low cost, low hypoglycemia risk, broad guideline support
DPP-4 inhibitors	Low hypoglycemia risk and oral administration
GLP-1 receptor agonists	Weight loss and improved glycemic efficacy
SGLT2 inhibitors	Cardiovascular and renal outcome benefits
Thiazolidinediones	Durable insulin sensitization, despite safety limitations
Insulin analogs	Greater potency in advanced disease

The commercial decline of Orinase was therefore not driven by one competitor. It resulted from successive waves of clinical substitution.

Generic price competition

Once tolbutamide became a generic product, the market shifted from brand differentiation to lowest-cost supply. Generic manufacturers competed primarily through wholesale acquisition cost, distributor access, and formulary status.

For an old oral tablet with no current patent barrier, generic pricing typically produces limited manufacturer revenue even when prescription volume remains stable. The product may remain available because manufacturing costs are low, but its commercial value is generally insufficient to support large sales and marketing investments.

What was Orinase’s financial trajectory?

Publicly reported Orinase-specific revenue data are not available in the standard financial disclosures of Upjohn, Pharmacia, Pfizer, or their successors. The product was historically sold within broad pharmaceutical portfolios, and company filings did not generally break out revenue for an individual legacy medicine.

The financial trajectory can therefore be characterized by market phase rather than by audited product-level revenue:

Financial phase	Revenue profile	Margin profile	Main driver
Initial launch	Rapid growth from first-in-class oral therapy adoption	High relative pricing power	Limited therapeutic alternatives
Expansion	Broad prescription uptake	Strong branded economics	Primary-care use and class adoption
Safety reassessment	Slower growth and declining share	Reduced pricing power	Cardiovascular and hypoglycemia concerns
Generic transition	Sharp branded revenue erosion	Margin compression	Multiple low-cost suppliers
Legacy period	Low and fragmented revenue	Low absolute profit	Residual use and supply economics

The largest economic value was created during the early branded period, when tolbutamide represented an important advance over insulin-dependent treatment for many patients with type 2 diabetes. The value declined as the product class matured and competitors improved treatment convenience and safety.

By the time modern diabetes franchises became central to pharmaceutical growth, Orinase had shifted from an innovation asset to a low-cost maintenance product. Its residual value was linked to manufacturing continuity and occasional clinical use rather than to brand equity or patent protection.

What generic entry risks exist for Orinase?

Generic entry risk is no longer the primary commercial issue because generic competition has already occurred. The relevant risks are product erosion and supply discontinuity.

Key factors include:

• Multiple potential manufacturers for an old active ingredient.
• Low barriers to tablet formulation.
• No meaningful current patent protection.
• Price-sensitive pharmacy and payer purchasing.
• Limited physician demand.
• Substitution by metformin and newer agents.
• Potential discontinuation if commercial volumes fall below manufacturing thresholds.

The absence of patent barriers means that a manufacturer cannot reliably defend market share through intellectual property. Product availability may depend more on procurement economics than on clinical demand.

Which companies are challenging Orinase?

No major current branded company appears to be challenging Orinase through a conventional Paragraph IV litigation strategy. The product’s commercial challenge comes from therapeutic competitors rather than patent litigants.

The competitive set includes manufacturers of:

• Metformin products.
• Glipizide, glyburide, and glimepiride.
• SGLT2 inhibitors such as empagliflozin and dapagliflozin.
• GLP-1 receptor agonists such as semaglutide and dulaglutide.
• DPP-4 inhibitors such as sitagliptin and linagliptin.
• Basal and mealtime insulin products.

These products compete for the same diabetes-treatment budgets but occupy different clinical and pricing segments.

What manufacturing and intellectual-property barriers affect tolbutamide?

Manufacturing barriers are low. Tolbutamide is a conventional small molecule administered as an immediate-release oral tablet. It does not require biologic production, sterile filling, complex device assembly, specialized cold-chain logistics, or sophisticated delivery technology.

The main operational barriers are commercial:

• Maintaining validated active pharmaceutical ingredient supply.
• Meeting current good manufacturing practice requirements.
• Maintaining dissolution and content-uniformity specifications.
• Supporting stability data and regulatory filings.
• Preserving distribution economics for a low-volume product.

There is no biosimilar risk because tolbutamide is a small molecule, not a biologic. Competition is governed through abbreviated generic pathways rather than biosimilar approval procedures.

How strong is the Orinase patent estate?

The Orinase patent estate is commercially weak to nonexistent in the current market. Its principal weaknesses are age, loss of composition-of-matter protection, absence of meaningful formulation differentiation, and therapeutic displacement.

Patent-estate factor	Current assessment
Composition-of-matter protection	Expired
Formulation protection	No material current barrier identified
Method-of-use protection	No material current barrier identified
Manufacturing protection	Low practical importance
Orange Book leverage	No meaningful current position
Paragraph IV exposure	No material branded litigation risk
Generic substitution risk	Already realized
Lifecycle-management potential	Minimal

What is the outlook for Orinase?

Tolbutamide’s outlook is stable only as a legacy generic, not as a growth pharmaceutical. Demand is likely to remain limited to patients for whom cost, historical familiarity, or local availability outweighs the clinical advantages of newer therapies.

Revenue potential is constrained by four structural factors:

1. The product is off patent.
2. Generic competition limits pricing.
3. Clinical guidelines favor other treatments.
4. Newer drugs offer benefits beyond glucose lowering.

A commercial revival would require a differentiated formulation, new clinical evidence, or a specialized market strategy. Existing product characteristics do not provide a credible basis for such a strategy.

Key Takeaways

• Orinase was the original U.S. brand for tolbutamide, a first-generation sulfonylurea.
• Its historical commercial success came from early adoption of oral therapy for type 2 diabetes.
• The product lost economic exclusivity many decades ago.
• No active patent estate, Orange Book position, or formulation barrier materially protects Orinase today.
• Safety concerns, particularly hypoglycemia and historical cardiovascular findings, weakened its position.
• Metformin, newer sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, and other modern therapies displaced tolbutamide.
• Orinase-specific revenue is not separately reported in public company filings.
• The current market is a low-value generic market with limited growth potential.
• There is no meaningful biosimilar exposure because tolbutamide is a small molecule.
• Current risk centers on product discontinuation and supply volatility, not patent litigation.

FAQs About Orinase and Tolbutamide

Is Orinase still sold in the United States?

The Orinase brand is not a meaningful current U.S. commercial product. Generic tolbutamide may be available from individual manufacturers or through limited distribution channels.

Is tolbutamide safer than metformin?

Metformin generally has a more favorable hypoglycemia profile when used alone and has stronger contemporary guideline support. Tolbutamide can cause clinically significant hypoglycemia because it directly stimulates insulin secretion.

Did Pfizer own the Orinase patent?

Orinase was historically associated with The Upjohn Company. Upjohn later became part of larger corporate transactions involving Pharmacia and Pfizer. Any original product patents are expired and no longer provide current exclusivity.

Can a company launch a new Orinase formulation?

A company could develop and seek approval for a new tolbutamide formulation, but the active ingredient is no longer protected by composition-of-matter exclusivity. Commercial success would depend on formulation differentiation, clinical utility, regulatory strategy, and payer acceptance.

Does Orinase have strategic value in diabetes licensing?

Orinase has little strategic licensing value as a standalone product. Any potential value would be limited to niche generic supply, regional distribution, or a broader portfolio of low-cost oral antidiabetic products.

References

1. American Diabetes Association Professional Practice Committee. (2024). Standards of care in diabetes - 2024. Diabetes Care, 47(Supplement 1).

2. University Group Diabetes Program. (1970). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes, 19(Supplement 2), 747-830.

3. U.S. Food and Drug Administration. (n.d.-a). Tolbutamide prescribing information and historical regulatory labeling. FDA.

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA.

5. National Library of Medicine. (n.d.). Tolbutamide: Drug information and historical clinical use. PubMed and DailyMed.